Intercept Pharmaceuticals Inc (NASDAQ:ICPT) reported financial results for the three months ended September 30, 2017, and provided other general business updates. “We are …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced additional results of the phase 2 clinical trial with obeticholic acid (OCA), a potent farnesoid X receptor agonist …
